Open Access Green as soon as Postprint is submitted to ZB.
HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA.
Gut 58, 1399-1409 (2009)
Background: Although histone deacetylase inhibitors (HDACi) are promising cancer therapeutics regulating proliferation, differentiation and apoptosis, molecular pathways engaged by specific HDAC isoenzymes in cancer are ill defined. Results: In this study we demonstrate that HDAC2 is highly expressed in pancreatic ductal adenocarcinoma (PDAC), especially in undifferentiated tumours. We show that HDAC2, but not HDAC1, confers resistance towards the topoisomerase II inhibitor etoposide in PDAC cells. Correspondingly, the class I selective HDACi valproic acid (VPA) synergises with etoposide to induce apoptosis of PDAC cells. Transcriptome profiling of HDAC2-depleted PDAC cells revealed upregulation of the BH3-only protein NOXA. We show that the epigenetically silenced NOXA gene locus is opened after HDAC2 depletion and that NOXA upregulation is sufficient to sensitise PDAC cells towards etoposide-induced apoptosis. Conclusions: In summary, our data characterise a novel molecular mechanism that links the epigenetic regulator HDAC2 to the regulation of the pro-apoptotic BH3-only protein NOXA in PDAC. Targeting HDAC2 will therefore be a promising strategy to overcome therapeutic resistance of PDAC against chemotherapeutics that induce DNA damage.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Times Cited
Scopus
Cited By
Cited By
Altmetric
9.766
3.000
75
127
Annotations
Special Publikation
Hide on homepage
Publication type
Article: Journal article
Document type
Scientific Article
Keywords
histone deacetylase inhibitor; topoisomerase-ii; valproic acid; gene-expression; trichostatin-a; in-vivo; ductal adenocarcinoma; leukemic-cells; cycle arrest; solid tumors
Language
english
Publication Year
2009
HGF-reported in Year
2009
ISSN (print) / ISBN
0017-5749
e-ISSN
1468-3288
Journal
Gut (eGut)
Quellenangaben
Volume: 58,
Issue: 10,
Pages: 1399-1409
Publisher
BMJ Publishing Group
Publishing Place
London
Reviewing status
Peer reviewed
POF-Topic(s)
30203 - Molecular Targets and Therapies
Research field(s)
Enabling and Novel Technologies
PSP Element(s)
G-505200-001
PubMed ID
19528037
Scopus ID
70349309923
Erfassungsdatum
2009-12-31